DGIdb - LEFLUNOMIDE Drug Record

LEFLUNOMIDE chembl:CHEMBL960 ApprovedAntineoplasticImmunotherapy

Alternate Names:

SULOL
LEFLUNOMIDE
SU-101
ARAVA
HWA-486
L04AA13
SU101
5-METHYL-N-(4-(TRIFLUOROMETHYL)PHENYL)-4-ISOXAZOLECARBOXAMIDE
HWA 486
LEFUNOMIDE
ARAVA®
LEFLUNOMIDA
ALPHA,ALPHA,ALPHA-TRIFLUORO-5-METHYL-4-ISOXAZOLECARBOXY-P-TOLUIDIDE
5-METHYLISOXAZOLE-4-CARBOXYLIC ACID (4-TRIFLUOROMETHYL)ANILIDE
LEFUNAMIDE
LEFLUNOMIDUM
ARABLOC®
chembl:CHEMBL960
drugbank:01097
chemidplus:75706-12-6
rxcui:27169
pubchem.compound:3899

Drug Info:

Year of Approval	1998
Drug Class	antirheumatic agents
FDA Approval	1998
Drug Class	small molecule
Drug Indications	Antirheumatic Agents

(5 More Sources)

Publications:

Schattenkirchner, 2000, The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical review., Immunopharmacology
Herrmann et al., 2000, Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases., Immunopharmacology
Wozel et al., 2002, [Leflunomide--a new drug for pharmacological immunomodulation]., Hautarzt
Reitzik et al., 1975, Familial polyostotic fibrous dysplasia., Oral Surg. Oral Med. Oral Pathol.
Li et al., 2004, Leflunomide in the treatment of rheumatoid arthritis., Clin Ther
Fukushima et al., Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice., Reprod. Toxicol.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Goldenberg, 1999, Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis., Clin Ther
Prakash et al., 1999, Leflunomide: a review of its use in active rheumatoid arthritis., Drugs
Fox, 1998, Mechanism of action of leflunomide in rheumatoid arthritis., J Rheumatol Suppl
Sanders et al., 2002, Leflunomide for the treatment of rheumatoid arthritis and autoimmunity., Am. J. Med. Sci.
Breedveld et al., 2000, Leflunomide: mode of action in the treatment of rheumatoid arthritis., Ann. Rheum. Dis.
Pawlik A et al., 2009, The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide., Pharmacogenomics
Bohanec Grabar P et al., 2009, Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis., Drug Metab Dispos
Bohanec Grabar P et al., 2008, Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients., Eur J Clin Pharmacol
Kullich et al., Inhibitory effects of leflunomide therapy on the activity of matrixmetalloproteinase-9 and the release of cartilage oligomeric matrix protein in patients with rheumatoid arthritis., Clin. Exp. Rheumatol.
Kraan et al., 2000, Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients., Arthritis Rheum.
Dziedziejko V et al., 2011, The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide., Pharmacogenomics

LEFLUNOMIDE DHODH

Interaction Score: 25.25

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dihydroorotate dehydrogenase inhibitor

Trial Name -

PMIDs:
10878295 10878294 12063741 1060033 15189743 17604599 11752352 10890256 10651393 9666414 12003373 11053058 19207032

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology PharmGKB
LEFLUNOMIDE MMP1

Interaction Score: 0.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16762150

Sources:
NCI
LEFLUNOMIDE CXCL8

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10902750

Sources:
NCI
LEFLUNOMIDE ESR1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21174621

Sources:
PharmGKB
LEFLUNOMIDE SMN2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LEFLUNOMIDE SMN1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LEFLUNOMIDE RAB9A

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LEFLUNOMIDE CYP1A2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19581389 18496682

Sources:
DTC PharmGKB
LEFLUNOMIDE HTT

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LEFLUNOMIDE ATAD5

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LEFLUNOMIDE NFE2L2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LEFLUNOMIDE CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: LEFLUNOMIDE
- Version: 01-August-2011
Alternate Names:

LEFLUNOMIDE Primary Drug Name

Drug Info:

Drug Class antirheumatic agents

Year of Approval 1998

Publications:
TdgClinicalTrial: LEFLUNOMIDE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antirheumatic Agents

Drug Class small molecule

FDA Approval 1998

Publications:

NCI: LEFLUNOMIDE

Version: 14-September-2017

Alternate Names:

C1128 NCI drug code

Drug Info:

Publications:

Kraan et al., 2000, Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients., Arthritis Rheum.

Kullich et al., Inhibitory effects of leflunomide therapy on the activity of matrixmetalloproteinase-9 and the release of cartilage oligomeric matrix protein in patients with rheumatoid arthritis., Clin. Exp. Rheumatol.

PharmGKB: leflunomide

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Bohanec Grabar P et al., 2009, Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis., Drug Metab Dispos

Bohanec Grabar P et al., 2008, Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients., Eur J Clin Pharmacol

Pawlik A et al., 2009, The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide., Pharmacogenomics

DTC: LEFLUNOMIDE
- Version: 02-September-2020
Alternate Names:

CHEMBL960 ChEMBL Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178103431
- Version: 29-September-2020
Alternate Names:

LEFLUNOMIDE GuideToPharmacology Ligand Name

Drug Info:

Publications:
TTD: Leflunomide
- Version: 2020.06.01
Alternate Names:

D08ROP TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL960
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL960
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Direct Interaction	yes
Mechanism of Interaction	Dihydroorotate dehydrogenase inhibitor
Trial Name	-

LEFLUNOMIDE Drug Record

LEFLUNOMIDE chembl:CHEMBL960 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Dihydroorotate dehydrogenase inhibitor Trial Name -

PMIDs: 10878295 10878294 12063741 1060033 15189743 17604599 11752352 10890256 10651393 9666414 12003373 11053058 19207032

Sources: DTC TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16762150

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10902750

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21174621

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19581389 18496682

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

TEND: LEFLUNOMIDE

Alternate Names: LEFLUNOMIDE Primary Drug Name

Drug Info: Drug Class antirheumatic agents Year of Approval 1998

Publications:

TdgClinicalTrial: LEFLUNOMIDE

Alternate Names:

Drug Info: Drug Indications Antirheumatic Agents Drug Class small molecule FDA Approval 1998

Publications:

NCI: LEFLUNOMIDE

Alternate Names: C1128 NCI drug code

Drug Info:

PharmGKB: leflunomide

Alternate Names:

Drug Info:

DTC: LEFLUNOMIDE

Alternate Names: CHEMBL960 ChEMBL Drug ID

Drug Info:

Publications:

GuideToPharmacology: 178103431

Alternate Names: LEFLUNOMIDE GuideToPharmacology Ligand Name

Drug Info:

Publications:

TTD: Leflunomide

Alternate Names: D08ROP TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL960

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dihydroorotate dehydrogenase inhibitor

Trial Name -

PMIDs:
10878295 10878294 12063741 1060033 15189743 17604599 11752352 10890256 10651393 9666414 12003373 11053058 19207032

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16762150

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10902750

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
21174621

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
19581389 18496682

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

LEFLUNOMIDE Primary Drug Name

Drug Info:

Drug Class antirheumatic agents

Year of Approval 1998

Drug Info:

Drug Indications Antirheumatic Agents

Drug Class small molecule

FDA Approval 1998

Alternate Names:

C1128 NCI drug code

Alternate Names:

CHEMBL960 ChEMBL Drug ID

Alternate Names:

LEFLUNOMIDE GuideToPharmacology Ligand Name

Alternate Names:

D08ROP TTD Drug ID